当前位置： SCI文献检索 > CURRENT MEDICAL RESEARCH AND OPINION期刊下所有文献 > Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.

Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.

Abstract：

OBJECTIVE:To investigate the efficacy of the cholesterol absorption inhibitor ezetimibe in patients with refractory familial hyperlipidaemia or intolerant to statin therapy. METHODS:This prospective study assessed the safety and efficacy of ezetimibe in 200 patients with refractory familial hyperlipidaemias not achieving a low-density-lipoprotein (LDL) cholesterol < 3 cholesterol < 3 mmol/L (116 mg/dL) including 22% intolerant to all statin therapy, many consuming intolerant to all statin therapy, many consuming sterol-containing products. RESULTS:Ezetimibe monotherapy resulted in 7% and 11% reductions in LDL-cholesterol and apolipoprotein B respectively. Ezetimibe-statin combination therapy reduced LDL-cholesterol by an additional 11 +/- 27% and apolipoprotein B by 11 (+79 to -18)%. There was a similar response between various sub-groups but a wide variation within groups with the greatest effect seen in patients groups with the greatest effect seen in patients under-responding to statins. The number of patients achieving the LDL-C target of 3 mmol/L rose from 5.5% to 18%. Non-significant effects included a 5 (+78 to -470)% reduction in triglycerides, 8 +/- 36% increment in HDL-cholesterol, 21 (+35 to -82)% reduction in C-reactive protein and a 1 (+20 to -50)% increase in alanine transaminase. No effects were seen on creatinine, creatine kinase, or insulin resistance. Fourteen patients (7%) discontinued ezetimibe: seven due to gastrointestinal side-effects, one patient developed an ezetimibe-induced hypercholesterolaemia (x 1.5), one developed ezetimibe-induced hypertriglyceridaemia (x 7) and five discontinued for other reasons. CONCLUSION:Ezetimibe is a useful addition to statins in patients with familial hyperlipidaemias but shows a highly variable response profile.

journal_name

Curr Med Res Opin

journal_title

Current medical research and opinion

authors

Wierzbicki AS,Doherty E,Lumb PJ,Chik G,Crook MA

doi

10.1185/030079905X28872

keywords:

subject

Has Abstract

pub_date

2005-03-01 00:00:00

pages

333-8

issue

eissn

0300-7995

issn

1473-4877

journal_volume

pub_type

临床试验,杂志文章

在线工具

Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.